Burden was greatly reduced with a digital tool set that informed evidence-based care with data on medication adherence, inhaler technique, and peak flow.
Durable benefits for endobronchial one-way SVS valves over only medical management for hyperinflation in severe heterogenous emphysema.
Pirfenidone in rheumatoid arthritis-associated interstitial lung disease failed its primary endpoint, but may benefit RAILD patients with usual interstitial pneumonia.
Cirrhotic patients had insufficient T cell reactivity after 2 mRNA vaccine doses. But a booster and a natural infection led to higher antibody levels in this group.
Early intervention with favipiravir did not improve clinical outcomes for hospitalised patients, but the agent may induce health benefits for patients under 60 years of age.
Deep learning from digitalised haematoxylin and eosin-stained whole-tumour slide images outperformed classical Miettinen relapse risks prediction.
Brensocatib did not improve the health status of patients with severe COVID-19. Active neutrophil elastase was decreased in treated patients without benefit.
Compared with usual care, a web-based, self-management support tool improved physical activity levels of COPD patients, suggest preliminary trial results.
Long-acting bronchodilators do not appear to improve respiratory symptoms in symptomatic tobacco-exposed individuals, Rethinc trial data suggests.
Corticosteroids improved lung function for premature children. A study suggests that bronchodilator responsiveness helps screening patients for this approach.
With an acceptable safety profile and promising efficacy data, nintedanib is a potential candidate for pediatric fibrosing interstitial lung disease treatment.
Treatment with nivolumab/ipilimumab for 4 weeks achieved a major pathological response in 95% of patients with stage III dMMR colon cancer.
Azithromycin should be avoided in early-life, severe rRSV bronchiolitis due to association with higher recurrent wheezing risks. Other antibiotics may have the same harmful effect.
In patients with SEA, continued reductions in clinically significant exacerbations were reported with mepolizumab administration after 2 years of follow-up.
After 24 weeks, the use of icenticaftor on top of triple inhalation therapy resulted in a clear dose-response on 5 endpoints in patients with COPD and chronic bronchitis.
A pharmacy-supported digital programme improved therapy and technique adherence for uncontrolled asthma patients, leading to better asthma control.
Point-of-care eosinophil-guided prednisolone was non-inferior to its standard-of-care prescription in treating COPD exacerbations, a trial showed.
Cardiology moves between life and death. The extent to which artificial intelligence could help or replace doctors in this field is a subject of passionate debate.
A trial demonstrated a doubling of PFS and a near doubling of overall survival with the VEGF-1, -2, and -3 inhibitor in patients with refractory mCRC.
According to a study, smokers suffer from heart failure more frequently than non-smokers of the same age. The underlying changes in the heart are visible.